🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications
Updated 04 Jul 2026 · HPRA open data

Irish Medicines Database

Every medicine authorised for the Irish market — 10,165 products with active substances, licence holders, dosage forms and prescription status.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9
28 results for “Ipsen”
MedicineActive substanceLicence holderStatus
Alluzience, 200 Speywood units/mL, solution for injection
PA1613/004/001
Botulinum Toxin A - Haemagglutinin Complex Ipsen Pharma Marketed
Azzalure, 125 Speywood units, powder for solution for injection
PA1613/001/001
Clostridium botulinum toxin type a haemagglutinin complex Ipsen Pharma Marketed
Bylvay 1 200 micrograms hard capsules
EU/1/21/1566/004
Odevixibat sesquihydrate Ipsen Pharma
Bylvay 200 micrograms hard capsules
EU/1/21/1566/001
Odevixibat sesquihydrate Ipsen Pharma
Bylvay 400 micrograms hard capsules
EU/1/21/1566/002
Odevixibat sesquihydrate Ipsen Pharma
Bylvay 600 micrograms hard capsules
EU/1/21/1566/003
Odevixibat sesquihydrate Ipsen Pharma
CABOMETYX 20 mg film-coated tablets
EU/1/16/1136/001-002
Cabozantinib Ipsen Pharma
CABOMETYX 40 mg film-coated tablets
EU/1/16/1136/003-004
Cabozantinib Ipsen Pharma
CABOMETYX 60 mg film-coated tablets
EU/1/16/1136/005-006
Cabozantinib Ipsen Pharma
COMETRIQ 20 mg hard capsules
EU/1/13/890/001
Cabozantinib (s)-malate Ipsen Pharma
COMETRIQ 80 mg hard capsules
EU/1/13/890/002-003
Cabozantinib (s)-malate Ipsen Pharma
Decapeptyl 3-month, 11.25 mgPowder and solvent for suspension for injection
PA0869/003/002
Triptorelin Ipsen Pharmaceuticals Limited Marketed
Decapeptyl 6-month 22.5 mg Powder and solvent for prolonged-release suspension for injection
PA0869/003/003
Triptorelin pamoate Ipsen Pharmaceuticals Limited Marketed
Decapeptyl SR, 3 mg powder and solvent for suspension for injection
PA0869/003/001
Triptorelin Ipsen Pharmaceuticals Limited Marketed
Dysport 300 units Powder for solution for injection
PA1613/002/002
Botulinum toxin type A - haemagglutinin complex Ipsen Pharma Marketed
Dysport 500 units Powder for solution for injection
PA1613/002/001
Clostridium botulinum toxin type a haemagglutinin complex Ipsen Pharma Marketed
Iqirvo 80 mg film-coated tablets
EU/1/24/1855/001
Elafibranor Ipsen Pharma
KAYFANDA 1200 microgram hard capsules
EU/1/24/1854/004
Odevixibat Ipsen Pharma
KAYFANDA 200 microgram hard capsules
EU/1/24/1854/001
Odevixibat Ipsen Pharma
KAYFANDA 400 microgram hard capsules
EU/1/24/1854/002
Odevixibat Ipsen Pharma
KAYFANDA 600 microgram hard capsules
EU/1/24/1854/003
Odevixibat Ipsen Pharma
NutropinAq 10 mg/2 ml solution for injection
EU/1/00/164/003-004
Somatropin Ipsen Pharma
NutropinAq 10 mg/2 ml solution for injection
EU/1/00/164/005
Somatropin Ipsen Pharma
Relfydess, 100 units/mL, solution for injection
PA1613/005/001
Botulinum Toxin Type A Ipsen Pharma Marketed
Salvacyl, 11.25 mg powder and solvent for prolonged-release suspension for injection
PA0869/008/001
Triptorelin Ipsen Pharmaceuticals Limited Not marketed
Somatuline Autogel 120mg, solution for injection in a pre-filled syringe
PA0869/004/004
Lanreotide acetate Ipsen Pharmaceuticals Limited Marketed
Somatuline Autogel 60 mg, solution for injection in a prefilled syringe
PA0869/004/002
Lanreotide acetate Ipsen Pharmaceuticals Limited Marketed
Somatuline Autogel 90mg, solution for injection in a pre-filled syringe
PA0869/004/003
Lanreotide acetate Ipsen Pharmaceuticals Limited Marketed
Cite this database

Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 13 August 2026).

Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.